Science Hub is Novo Nordisk’s one-stop portal for all our scientific publications and clinical trials, congress materials and medical updates. Sign up to gain full access.
Zenagamtide (Amycretin), a Novel Unimolecular GLP-1 and Amylin Receptor Agonist: Phase 2b Results in T2D
Authors:
Pablo Mora1,2; Vanita R Aroda3; Marisse Asong4; Matthias Blüher5; Line Dam Heftdal4; Amanda-Louise Fenger Carlander4; Louise Nygaard Vilsen4; Julio Rosenstock1